Detyrosinated microtubules provide mechanical resistance that can impede the motion of contracting cardiomyocytes. However, the functional effects of microtubule detyrosination in heart failure or in human hearts have not previously been studied. Here, we utilize mass spectrometry and single-myocyte mechanical assays to characterize changes to the cardiomyocyte cytoskeleton and their functional consequences in human heart failure. Proteomic analysis of left ventricle tissue reveals a consistent upregulation and stabilization of intermediate filaments and microtubules in failing human hearts. As revealed by super-resolution imaging, failing cardiomyocytes are characterized by a dense, heavily detyrosinated microtubule network, which is associated with increased myocyte stiffness and impaired contractility. Pharmacological suppression of detyrosinated microtubules lowers the viscoelasticity of failing myocytes and restores 40-50% of lost contractile function; reduction of microtubule detyrosination using a genetic approach also softens cardiomyocytes and improves contractile kinetics. Together, these data demonstrate that a modified cytoskeletal network impedes contractile function in cardiomyocytes from failing human hearts and that targeting detyrosinated microtubules could represent a new inotropic strategy for improving cardiac function.
D
uring the transition from cardiac hypertrophy to failure, structural changes to the ventricular myocyte impair systolic and diastolic function. A proliferated microtubule network has been proposed 1 , and subsequently refuted 2 , as a possible contributor to impaired performance. Certain studies in animal models of pressure overload-induced cardiomyopathy indicate a substantial impairment of myocyte contraction by proliferated microtubules 1, 3, 4 , while others show no such role 2, 5 . Inconsistencies have been attributed to the severity of the disease stimulus required to cause microtubule proliferation, raising the question of relevance in human heart failure. To circumvent discrepancies between model systems, we utilized human myocardium and myocytes from heart failure subjects, where the role of microtubules is unexplored.
Our previous work in murine myocytes indicates that the mechanical contribution of microtubules depends not only on the proliferation of the network, but also on its post-translational modification 6, 7 . Microtubules undergo a switch in mechanical behavior between low-resistance sliding and high-resistance buckling due to interactions with the sarcomere mediated at least partly by desmin intermediate filaments. This switch is governed by post-translational detyrosination (dTyr) of microtubules, which promotes the buckling behavior and crosslinking of cytoskeletal networks, increasing viscoelastic resistance to sarcomere shortening and stretch 7, 8 . While previous work suggests both desmin 9 and dTyr 7 may be elevated in heart failure, the extent of these changes and their functional ramifications are untested.
Thus, there were two major goals of this study. First, to broadly characterize how the cardiac cytoskeleton is changed in human heart disease of various etiology and severity. Second, to directly test whether detyrosinated microtubules regulate the mechanics of human cardiomyocytes from non-failing and failing hearts. Together, our results support the attractiveness of detyrosinated microtubules as a target for therapeutic intervention.
Results
This study utilized left ventricular myocardium from 105 nonfailing and failing human hearts. Non-failing hearts are subdivided into normal or compensated hypertrophy (cHyp), while failing hearts are subdivided into ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM) with preserved or reduced ejection fraction (HCMpEF and HCMrEF, respectively). Western blot was performed on 102 hearts; 34 of these were also used for mass spectrometry, while 22 were used for primary isolation of cardiomyocytes for functional studies. For further details on subject classification, in vivo parameters, and the experiments performed on each heart, see Methods and Supplementary Table 1 .
Conserved upregulation and stabilization of microtubules and intermediate filaments across human heart failure. First, we sought to globally characterize changes to the cytoskeletal proteome that occur in human heart disease. Tandem mass spectrometry analysis detected 3,764 proteins in left ventricular tissue, and there was a distinct proteomic distribution based on subject etiology (Fig.  1a, Supplementary Fig. 1b -e, Supplementary Data). Principal component analysis (PCA) was used to examine and display the variance in protein distribution among groups, and demonstrates that non-failing hearts are well separated from failing hearts. Among
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Articles NATure MeDiciNe failing hearts, the proteomic profiles of non-ischemic heart disease (HCM and DCM) cluster tightly together, while those from ischemic hearts demonstrate a distinct proteomic profile. Non-myocyte populations will contribute to these proteomic profiles but, given their small contribution to tissue mass and modest change in this contribution observed in failing hearts ( Supplementary Fig. 2d ) 10 , the dominant shifts in myocyte proteins likely arise from within that population. SVIL  DES  DDAH1  PGM5  SYNM  RTN3  SLMAP  MXRA7  APOA4  PPP1R12C   THBS4  HSPA2  NES  DDAH1  AHSG  MAP4  DES  MXRA7  ARHGAP1 Tables 3 and 4 . GDP, guanosine diphosphate; GO, gene ontology; mRNA, messenger RNA; rRNA, ribosomal RNA; c, Heat map depicting the expression levels (log 2 fold change) of individual proteins in the major cytoskeletal subgroups. NF, non-failing. d, Table, top ten upregulated genes as obtained from differential gene expression analysis in HCMrEF and DCM (compared to normal). Cytoskeletal genes are highlighted in red. Dot plots, abundance of specific proteins of interest measured as LFQ value from mass spectrometry data. Each data point represents one heart, with mean line and whiskers representing s.d. Statistical significance was determined via differential gene expression analysis compared to normal hearts, in which a linear model adjusting for age and sex in the R package LIMMA was used. P values were adjusted for multiple testing using the Benjamini-Hochberg procedure.
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We ranked the protein list for each subject group based on the significance of the change in protein expression compared to normal hearts. The top 25 up-and downregulated proteins from each subject group are displayed in Supplementary Table 2 . Gene ontology analysis 11 was used to determine the most robustly changed molecular functions in each subject population relative to normal hearts (Fig. 1b) . In cHyp, the most prominent increases were in gene ontology groups related to mitochondrial function or redox balance. In ICM, significant upregulation in endopeptidases and proteins involved in immune and inflammatory responses was observed. Yet in non-ischemic heart failure, particularly in HCMrEF and DCM, three of the five most significantly upregulated gene ontology groups encoded cytoskeletal proteins (Fig. 1b, Supplementary  Table 3 ). This pattern is also evident in protein domain analysis, where tubulin, spectrin, and CH-type domains are the most prominently increased in non-ischemic (but not ischemic) heart failure (Supplementary Table 4) .
We further examined the expression profiles of the individual proteins driving these cytoskeletal changes. Figure 1c demonstrates protein expression of the major cytoskeletal subgroups-intermediate filament proteins, tubulin, and actin/myosin. Intermediate filament proteins show a pronounced and progressive upregulation from cHyp to end-stage heart failure. The major tubulin isotypes are also progressively, but more modestly, increased. Conversely, most actin and myosin isoforms, including sarcomeric actomyosin, tend to decrease in relative abundance in disease.
In Fig. 1d we highlight several specific proteins of interest. In end-stage failing hearts, many of the most upregulated proteins are cytoskeletal in nature. Thrombospondin-4 (gene: THBS4) and supervilin (gene: SVIL) are involved in linking the plasma membrane to the external matrix and to the internal cytoskeleton 12, 13 . Microtubule associated protein 4 (gene: MAP4) is the predominantly expressed MAP in the heart. It can bind and stabilize cardiac microtubules, as well as promote dTyr and resistance to myocyte contraction 14, 15 . MAP4 is increased in every subject sample compared to any normal control, suggesting a highly conserved upregulation of this microtubule stabilizer in human heart disease. Finally, while most tubulin isoforms are synthesized with a C-terminal tyrosine, α -tubulin A4A (gene: TUBA4A) is synthesized in its detyrosinated form 16 . Thus, increases in both MAP4 and TUBA4A proteins are predicted to increase the amount of stable, detyrosinated microtubules in failing human hearts.
Together, this proteomic analysis suggests that the upregulation and stabilization of the cytoskeleton-specifically microtubules, intermediate filaments, and proteins associated with linking the cytoskeleton to the external environment-is a prominent feature of end-stage heart failure in humans.
Proliferation and modification of microtubules and intermediate filaments in diseased human myocytes. To validate and extend our proteomic results, we performed quantitative western blot and immunofluorescence analyses of cytoskeletal targets in human myocardium and myocytes. As microtubules tend to fragment during fixation of myocardial tissue (see Methods, Supplementary Fig.  2b ), we examined the network organization in isolated left ventricular myocytes using super-resolution imaging. Just under the membrane, cortical microtubules are chaotically organized and show frequent transverse elements, while deeper into the cell the network becomes quite dense, with interior microtubules predominantly aligned along the long axis of the myocyte (Fig. 2a, Supplementary  Video 1 ). This organization is mostly conserved between failing and non-failing myocytes ( Supplementary Fig. 3 ), in contrast to the network disorganization seen in myopathies that arise from the loss of costameric proteins 7, 17 . Structured illumination microscopy (SIM) of the interior microtubules in a normal human myocyte reveals an intricate network, predominantly formed by single or paired microtubules running tens of microns in the cell, forming a lattice-like structure with transverse desmin filaments (Fig. 2b) . As recently observed in murine myocytes 7 , these longitudinal microtubules buckle predominantly between sarcomeric Z-disks during contraction, suggesting that they bear compressive load. This periodic buckling was observed in both non-failing and failing cardiomyocytes ( Supplementary Videos 2 and 3) .
The microtubule network is highly proliferated and detyrosinated in failing versus non-failing myocytes (Fig. 2c,d ). Quantitative image analysis reveals that the fraction of cell area covered by all microtubules or dTyr-microtubules increases by 1.5-and 2-fold, respectively, in failing myocytes (Fig. 2d bottom left), with a significant increase in the ratio of dTyr to total microtubules ( Fig. 2d bottom right) . This increase in microtubule density is concomitant with an increase in total tubulin protein, as western blotting of left ventricular tissue shows a significant upregulation of α -tubulin in HCM, DCM, and ICM hearts (Fig.  2f, Supplementary Fig. 2a ).
In addition, failing myocytes demonstrate a distorted arrangement of desmin and misaligned myofibrils ( Supplementary Fig.  2b ,c,e). Quantification of desmin organization shows reduced periodicity in failing left ventricular myocardium, but not in cHyp hearts ( Supplementary Fig. 2c ). Western blot analysis demonstrates a marked upregulation of desmin in human heart failure ( Fig.  2e,f) . Interestingly, we observed multiple bands below desmin's predicted molecular weight; some of these low-molecular-weight bands were previously identified as post-translationally modified desmin products that are prone to misfolding, aggregation, and cleavage 9 . These low-molecular-weight products were increased above the mean level of non-failing hearts in 57 out of 60 failing hearts (Fig. 2e,f) .
Microtubules increase viscoelasticity in failing myocytes. Next, we sought to test whether detyrosinated microtubules differentially affect the mechanical properties of failing versus non-failing myocytes. To assess passive mechanics, viscoelasticity was measured via transverse nano-indentation and variable indentation-rate viscoelastic analysis 18 . Briefly, myocytes were indented at progressively increasing rates to evaluate elastic as well as viscoelastic contributions to myocyte stiffness. As seen in Fig. 3a , stiffness increases as a function of indentation rate, demonstrating that human myocytes are indeed viscoelastic. The elastic modulus (E) at the lowest velocity arises primarily from elastic components within the myocyte (E min ), while high velocity stiffness reflects both elastic and viscous contributions (E max ). The change in modulus with rate is a useful indicator of viscoelasticity (Ε∆ ). Failing myocytes showed no difference in E min (Fig. 3a,b left E min , DMSO-treated cells), but were significantly more viscoelastic than non-failing myocytes (Fig. 3a ,b E max and E∆ , DMSO-treated cells). Next, we tested the contribution of microtubules and microtubule dTyr to this increased viscoelasticity. Parthenolide (PTL) inhibits the detyrosinating enzyme tubulin carboxypeptidase, which catalyzes the removal of the C-terminal tyrosine from α -tubulin. PTL (10 μ Μ ) suppresses dTyr in cardiac and skeletal muscle without grossly disrupting microtubule density 6, 7 , while 10 μ M colchicine (colch) broadly depolymerizes microtubules 1 . No differences in elasticity were observed between non-failing and failing myocytes in any treatment condition (Fig. 3a,b left, E min ). While microtubule destabilization had a modest effect on normal myocytes, both colch and PTL treatment robustly reduced viscoelasticity in failing myocytes (Fig. 3b , E max and E∆ ), indicating that the proliferation of dTyr-microtubules increases transverse stiffness in human heart failure. Figure 3c provides a summary of these studies, plotting the drug-induced decrease in viscoelasticity relative to the initial stiffness of each heart tested. In general, stiffer myocytes show larger reductions in viscoelasticity after destabilizing microtubules or suppressing dTyr. Bottom, a higher magnification image of transverse desmin elements (magenta) and longitudinal microtubules (cyan). c, Representative dTyr-and Tyrmicrotubule networks in non-failing and failing myocytes. dTyr-tub, detyrosinated tubulin; Tyr-tub, tyrosinated tubulin. d, Top, immunofluorescent images were converted to binary images to quantify microtubule network density. Bottom, the percentage of cell area covered by polymerized microtubules (left) and the ratio of dTyr-microtubule/total microtubule (right). The total microtubule network density was calculated from the overlay of dTyr-microtubule and Tyr-microtubule binary images. a,c,d, Non-failing, n = 68 images from 68 myocytes from N = 3 biologically independent hearts; failing, n = 42 images from 42 myocytes from N = 2 biologically independent hearts. Each dot represents an individual myocyte with mean line and s.d. Statistical significance in d determined via two-sided t-test with post hoc Bonferroni correction, *P versus non-failing. e,f, Representative western blot of desmin (e) and quantification of the levels of α -tubulin and the 53-kDa and low-molecular-weight forms of desmin (f). MW, molecular weight; Norm., normal. GAPDH was used as a loading control. Each dot represents an individual heart with mean line and s. 
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NATure MeDiciNe dTyr-microtubules impede contractility in failing myocytes. If dTyr-microtubules provide viscoelastic resistance, removing them should reduce this resistance, improving contractility. Thus, we assessed sarcomere lengths and contractile velocities during electrical stimulation of 785 freshly isolated myocytes from 12 human hearts, 7 failing and 5 non-failing (for subject characteristics, please see Supplementary Table 1) . Prior to treatment, failing myocytes demonstrated markedly reduced sarcomere shortening, with slower contraction and relaxation velocities compared to non-failing cells (Fig. 4a,e) . Figure 4b ,c depicts average traces of myocyte shortening with and without microtubule destabilization from five representative non-failing and failing hearts of different etiologies. On average, non-failing myocytes treated with colch showed modest (yet significant) increases in shortening amplitude and contractile velocities ( Fig. 4b left) , as quantified in Fig. 4f . PTL had even less of an effect on non-failing myocytes, actually slightly prolonging the late phase of relaxation ( Fig. 4b(right), g ). Yet in failing myocytes, both colch and PTL robustly improved shortening amplitude and velocity and increased the speed of relaxation (Fig. 4c,f,g ). The average velocity traces from all cells are shown in Fig. 4d -neither colch nor PTL fully rescued contractile velocities of failing myocytes back to the non-failing benchmark, but restored ~40-50% of lost function. Notably, the treatment-induced improvement in contractile kinetics from a given heart was inversely correlated with the initial contractile kinetics prior to treatment (Fig. 4e) . Put differently, hearts with slowly contracting myocytes benefitted most from microtubule destabilization, raising the possibility of predicting therapeutic efficacy based on initial functional assessment. Of interest, myocytes from a failing heart with preserved ejection fraction (HFpEF) showed the slowest contractile duration and largest improvement in relaxation time upon suppression of detyrosinated microtubules (Fig. 4c right) .
Upstream changes in excitation-contraction coupling could also contribute to the contractile alterations observed upon microtubule destabilization, for which there is precedent in the literature 19 . We thus measured electrically stimulated [Ca 2+ ] i transients in failing and non-failing myocytes with colch and PTL treatment ( Supplementary  Fig. 4 ). [Ca 2+ ] i transients exhibited reduced amplitudes and slowed kinetics in failing myocytes, suggesting that defects in excitationcontraction coupling likely contribute to their observed contractile dysfunction (Fig. 4a) . However, neither colch nor PTL treatment improved this impaired [Ca 2+ ] i cycling ( Supplementary Fig. 4e ), suggesting that the microtubule-dependent augmentation in contractility is primarily mechanical in origin. Colch had no significant effect on Ca 2+ cycling in any group, while PTL treatment actually prolonged the [Ca 2+ ] i transient decay phase in non-failing myocytes ( Supplementary Fig. 4c,g ). As discussed further below, this slowed [Ca 2+ ] i removal may explain the prolonged late relaxation in PTL-treated non-failing myocytes (compare Supplementary  Fig. 4c and Fig. 4b ). Regardless, from these studies we conclude that . Data are presented as myocyte mean ± s.e.m. b, Quantification of viscoelasticity measurements E min (minimum stiffness at low rate), E max (maximum stiffness at high rate), and EΔ (difference between E min and E max , an indicator of viscoelasticity). Each data point represents a single myocyte with mean line and whiskers as s.d. Detailed measurements from each heart are available in Supplementary Table 5 . Statistical significance determined via one-way ANOVA with post hoc Tukey test, *P versus DMSO; #P versus non-failing. NS, not significant. c, Correlation between the initial viscoelasticity (E∆ ) of each heart and the percentage decreases in viscoelasticity after colch (square) and PTL (circle) treatment. Each data point represents the mean E∆ from all cells in a particular heart, which are color coded by group. Rx, treatment. Genetic modification of tubulin tyrosination lowers stiffness and improves contractility. We next aimed to validate these pharmacologic findings with a genetic approach, particularly given potential off-target effects of PTL. While the aforementioned tubulin carboxypeptidase detyrosinates microtubules, this process can be readily reversed by tubulin tyrosine ligase (TTL), which catalyzes the readdition of the tyrosine residue to α -tubulin tails (for review see 20 )
. Adenoviral overexpression of TTL (AdV-TTL) for 48 h in cultured human cardiomyocytes decreased the density of dTyr-microtubules and the proportion of total microtubules that were detyrosinated, while also producing a slight drop in overall microtubule density compared to myocytes infected with a null encoding adenovirus (AdV-null) (Fig. 5a) . TTL overexpression led to a significant increase in shortening amplitude and velocity in these myocytes, and increased relaxation velocities approximately two-fold (Fig. 5b-d) . Stiffness measurements confirmed a large reduction in viscoelasticity in AdV-TTL myocytes compared to AdV-null (Fig. 5e,f) , suggesting that contractile improvements are at least partly attributable to reduced internal resistance. While contractility experiments were typically performed at 0.5 Hz stimulation at room temperature, we also tested whether similar improvements were observed at physiological temperature and pacing frequency. At 37 °C all contractile parameters were similarly improved by TTL overexpression, and the magnitude of improvement was unchanged with either 0.5 or 1 Hz stimulation ( Supplementary Fig. 5 ). Of note, the late phase of relaxation was significantly faster with TTL overexpression (Fig. 5b,d right, Supplementary Fig. 5 ), in contrast to the prolongation of this component with PTL treatment. This suggests an off-target effect of PTL, as opposed to an on-target consequence of suppressing dTyr. Together, these results suggest that genetic manipulation of tyrosination/detyrosination (Tyr/dTyr) balance represents a potent and specific tool to modulate contractility in human myocytes.
discussion
From the above we arrive at three major conclusions. First, the increased expression and stabilization of the non-sarcomeric cytoskeleton is a consistent feature of end-stage heart failure. Second, an endogenously proliferated and modified microtubule network contributes viscoelastic resistance that impedes myocyte motion in heart failure. And third, destabilizing dTyr-microtubules significantly lowers stiffness, enhances contractility, and increases relaxation velocity in failing, human, left ventricular myocytes.
Our data suggest that whether dilated or hypertrophic in morphology, end-stage failing hearts share a surprisingly overlapping proteome. A dominant feature is the increased expression of cytoskeletal proteins, particularly intermediate filaments and microtubules. We speculate that similar to other aspects of cardiac remodeling these changes may initially be adaptive, perhaps to protect a heart under high mechanical stress, but become maladaptive when sufficiently progressed.
Our results in diverse cases of heart failure complement previous correlative studies in subjects with aortic stenosis 21 and in animal models that show microtubule proliferation following a variety of disease stimuli, including (but not limited to) left ventricular pressure overload (dog 3 ; mouse 22 ), right ventricular pressure overload (cats 1 ), drug-induced pulmonary hypertension (rats 23, 24 ; calf 25 ), dystrophic cardiomyopathy (mouse 26, 27 ), and diabetic cardiomyopathy (rats 28 ). However, replication studies in left ventricular overload models have also failed to show tubulin upregulation (guinea pig 2, 29 ; cats 5 ), and contractility rescue via colch is far from consistent 2, 5, 23 . Here, functional tests on human myocytes provide clinically relevant evidence to revitalize and refine the pursuit of modified microtubules as a therapeutic target in heart disease.
In aggregate, our data suggest that proliferated, detyrosinated microtubules act as compression resistance elements to impair contraction in the failing heart. The efficacy of PTL treatment on stiffness and contractility-independent of an improvement in [Ca 2+ ] i cycling or gross reduction in network density 6, 7 -is best explained by a disruption in the interaction between dTyr-microtubules and the sarcomere, which lowers the compression resistance provided by a cross-linked cytoskeletal network 7 . In this light, the lesser effect of colch and PTL treatment on non-failing myocytes suggests that, in these cells, cytoskeletal resistance was insufficient to markedly impede contractility. This may be explained by a simple lack of microtubule density or dTyr beyond a critical level, or resistance may be limited by the availability of microtubule interacting partners such as desmin. In support of this hypothesis, myocytes lacking desmin appear insensitive to PTL, presumably due to the loss of a microtubule-intermediate filament crosslink 7 . Thus, the efficacy of microtubule destabilization may depend on the proliferation of intermediate filaments that support the formation of a dense, crosslinked cytoskeletal network. Of note, both full-length desmin and lower-molecular-weight products linked to aggregation were markedly upregulated in heart failure samples here and in a previous examination of dyssynchronous heart failure 9 . The contribution of modified desmins to viscoelasticity and proteotoxicity demands further investigation.
We observed the largest improvements in contractile velocities with the tyrosination of microtubules by AdV-TTL in cultured myocytes. Given the reduced microtubule network density and viscoelasticity in these cells, this improvement is likely attributable to reduced internal resistance. However, additional mechanisms may be at play, and warrant discussion when considering chronic effects of suppressing dTyr-microtubules. Prolonged destabilization of microtubules can prevent some of the adverse remodeling of the T-tubule system and subsequent disruption of excitation-contraction coupling that occurs in both heart failure and cell culture 22, 24 . Further, suppressing dTyr has specifically been shown to reduce the generation of mechanical stress-induced reactive oxygen species, which could also benefit cell function by minimizing oxidative stress 6, 26 . Microtubules also regulate mitochondrial positioning in cardiomyocytes 30 and broadly regulate vesicular transport, although any role of dTyr in these processes remains to be explored.
Regardless of these confounding factors, the genetic modification of Tyr/dTyr balance represents a targeted approach with significant potential to sustainably improve both systolic and diastolic function. Our results suggest the improvement in myocyte function will likely correlate with the degree of myocyte stiffening and the slowing of contractile velocities, which will vary with disease etiology and severity. Further, while myocyte mechanics regulate whole organ function, this relationship is complex and will depend on numerous contributing factors. For example, in an ischemic, heavily fibrotic heart, tissue stiffness may be largely determined by the infiltrative extracellular matrix, potentially rendering a microtubule contribution nominal; yet in idiopathic or congenital myopathy with minimal fibrosis, myocyte specific changes, such as those contributed by microtubules and/or titin, would be predicted to play a more dominant role.
Given its potential as a novel inotrope, the clinical value of targeting microtubules for the treatment of heart failure should be re-evaluated. The daily dose of oral colch for subjects with gout is typically 1 mg, which gives rise to mean peak plasma concentrations of ~10-30 nM 31 . While tissue levels may differ from that in serum, this concentration is at least an order of magnitude lower than the dosage required to depolymerize cardiac microtubules. The ratio of benefit to adverse effects is already poor with this dosage 32 , suggesting that sufficiently high concentrations of colch may be difficult to achieve in subjects. Manipulating Tyr/dTyr balance represents a more refined therapeutic approach that largely spares , a finding that would be explained by an off-target effect of PTL on Na 2+ / Ca 2+ exchanger activity, as human myocytes rely more heavily on Na 2+ /Ca 2+ exchanger for the removal of cytosolic Ca 2+ during relaxation. Promisingly, this prolonged relaxation is absent in TTL over-expressing human myocytes, suggesting that more specific pharmacologic or genetic approaches to manipulate Tyr/dTyr balance should be pursued.
Finally, there is reason for optimism on the success of a microtubulebased inotropic strategy where others have failed. Currently available inotropes, such as dobutamine and milrinone, are endorsed for stabilization of patients with cardiogenic shock, as a bridge to transplant or longterm mechanical circulatory support, or as palliative therapy 33 , because their long-term use may actually worsen patient outcomes 34 . This is at least partly attributed to the increased metabolic cost and arrhythmia risk associated with chronically augmenting Ca 2+ cycling or force production. Destabilizers of a dense cytoskeletal network would theoretically represent a new class of energetically neutral inotropes, which do not force the cell to burn more ATP, but simply lower the resistance the myocyte must work against to improve both systolic and diastolic performance. and dTyr-microtubule/total microtubule ratio (as described in Fig. 2d ) following adenoviral-mediated overexpression of TTL (TTL) in cultured human cardiomyocytes, compared to myocytes infected with a null encoding adenovirus (Null). Null, n = 32 myocytes from N = 2 biologically independent hearts; TTL, n = 31 myocytes from N = 2 biologically independent hearts. b, Average traces of sarcomere shortening in AdV-Null and AdV-TTL overexpressing cardiomyocytes. c, Average contractile velocities of AdV-Null and AdV-TTL overexpressing cardiomyocytes (first derivative of (c)). d, Quantification of contractile parameters. Each data point represents a single cardiomyocyte infected with AdV-null (n = 80) or AdV-TTL (n = 77) from N = 3 biologically independent hearts. e, Viscoelasticity data (presented as mean ± s.e.m.). f, Quantification of viscoelasticity measurements on AdV-TTL and AdV-null expressing myocytes, presented as and quantified as described in Fig. 3. a,b,d . Failing hearts are etiologically defined by clinical diagnosis of HCM, which is subdivided into HCM with preserved ejection fraction (HCMpEF ejection fraction > 50%) and HCM with reduced ejection fraction (HCMrEF ejection fraction < 50%). Failing hearts with dilated left ventricular chamber size are classified as DCM, and failing hearts with ischemic injury are grouped as ICM. A proportion of the failing hearts manifest a combination of mixed ischemic and dilated etiology.
Thirty-four hearts in total were used in mass spectrometry (see method details below), including 7 normal, 6 cHyp, 4 HCMpEF, 5 HCMrEF, 6 DCM, and 6 ICM. Myocytes were isolated from 22 hearts (see method details below) for functional studies, including 6 normal, 7 cHyp, and 9 failing transplants (hearts with ejection fraction < 50%, including 6 DCM, 1HCMpEF, 1 HCMrEF, 1 ICM). All data collected from these subjects are included in this study. For further details on classification, descriptive statistics, and experiments performed on each heart and a summary see Supplementary Table 1 .
Human left ventricular myocyte isolation. Hearts received cold, bloodcontaining, high-potassium cardioplegic solution in vivo. Explanted hearts were transported from the operating suite to the laboratory in cold Krebs-Henseleit buffer (KHB) solution (12.5 mM glucose, 5.4 mM KCl, 1 mM lactic acid, 1.2 mM MgSO 4 , 130 mM NaCl, 1.2 mM NaH 2 PO4, 25 mM NaHCO 3 , and 2 mM Na pyruvate, pH 7.4). Myocytes were disaggregated by use of a modification of isolation techniques described previously 36 . Briefly, hearts were weighed and rinsed in KHB. A non-infarcted free wall region of the left ventricular apex was dissected and a small catheter was placed into the lumen of the left ventricular descending artery. Major large vessels on the tissue piece were identified by injecting KHB via the cannula and tied by suture knots to improve perfusion via small vessels. Once the tissue was ready for perfusion, it was covered by plastic wrap with pores for outflow, in order to maintain tissue temperature at 37 °C. The cannulated left ventricular tissue was perfused with a non-recirculating Ca 2+ -free solution (KHB containing 20 mM BDM and 10 mM taurine) for 10-15 min until the outflow temperature reached around 37 °C. Then, 200 ml of KHB containing 294 units ml −1 collagenase, 20 mM BDM, and 10 mM taurine was perfused for 3 min without recirculation followed by 22-32 min with recirculation (depending on the cannulation and how fibrotic the tissue was). Ca 2+ was introduced stepwise per minute by adding CaCl 2 solution up to 1 mM (that is, 4 × 50 μ M, 4 × 100 μ M, and 2 × 200 μ M) into the recirculated collagenase solution. Then the tissue was perfused for 5 min with rinse solution (KHB containing 10 mM taurine, 20 mM BDM, 1 mM CaCl2, and 1% BSA). The tissue was then removed from the cannula, and myocardial tissue was minced in the rinse solution and triturated using glass pipets. The resulting cell suspension was filtered through 280-μ m nylon mesh (component supply U-CMN-280), centrifuged (25 × g for 2 min), and resuspended in rinse solution. The temperature was maintained at 37 °C throughout the isolation. Viable cells were enriched by gravity sedimentation for 5 min, and the resulting loose pellet was transferred to a fresh tube and resuspended in the proper amount of normal Tyrode's solution for contractility, [Ca 2+ ] i transients, and nanoindentation. Cells were also fixed for immunofluorescence (see details below).
Mass spectrometry of human left ventricular tissues. Sample preparation.
Human left ventricular tissues collected from a myocardial rich, minimally fibrotic region of the mid left ventricular wall were used for mass spectrometry. Tissue was homogenized in ice-cold RIPA lysis buffer containing 0.1% SDS (Cayman 10010263) supplemented with protease inhibitor cocktail (Sigma). Protein concentration was determined by protein assay dye reagent (Bio-Rad 5000205). Protein (100 μ g) from each sample was precipitated as previously described 37 .
The pellet was resuspended with 8 M urea, 100 mM NH 4 HCO3, and pH 8.0. Denaturation/reduction was performed in 8 M urea, 5 mM dithiothreitol, and 25 mM NH 4 HCO 3 (pH 8.0) for over 60 min at 52 °C. The solution was stored at room temperature in 25 mM iodoacetamide in the dark for 60 min. The urea was diluted to a concentration of 1 M with 25 mM NH 4 HCO 3 and then digested with trypsin (1:50 ratio) at 37 °C with shaking for 16 h. After tryptic digestion, the peptide mixture was desalted with C18 micro spin column (Harvard Apparatus, Holliston, MA). The column was washed with 200 μ l 100% acetonitrile and equilibrated with 200 μ l loading buffer (0.1% formic acid). Peptides were loaded onto the column, washed with a loading buffer, and eluted with 200 μ l 70% acetonitrile, 0.1% formic acid. All steps for loading, washing, and elution were carried out with benchtop centrifugation (300 × g for 2 min). The eluted samples were dried in a centrifugal vacuum concentrator and reconstituted with 0.1% formic acid.
Nano liquid chromatography and mass spectrometry. Desalted peptides were analyzed on a Q-Exactive (Thermo Scientific) attached to an EasyLC system run at 300 nl min −1
. Peptides were eluted with a 170 min gradient from 2% to 32% acetonitrile and to 98% acetonitrile over 10 min in 0.1% formic acid. Datadependent acquisition mode with a dynamic exclusion of 45 s was enabled. One full mass spectrometry (MS) scan was collected with scan range of 350-1,600 m/z, resolution of 70,000, maximum injection time of 50 ms, and automatic gain control of 1E6. Then, a series of tandem MS scans were acquired for the most abundant ions from the full MS scan (top 12). Ions were filtered with charge 2-4. An isolation window of 2.0 m/z was used with quadruple isolation mode. Ions were fragmented using higher-energy collisional dissociation with collision energy of 27%. Orbitrap detection was used with scan range of 200-2,000 m/z, resolution of 17,500, maximum injection time of 150 ms, and automatic gain control of 5E6.
Proteomics mass spectrometry data analysis including peptide identification and quantification. MaxQuant version 1.5.3.30 was used to process the raw spectra 38 . The uniprot human database was used for database searching. Default search parameters were used, including precursor mass tolerance of 20 ppm, fragment mass tolerance of 20 ppm, trypsin cleavage, and up to 2 mis-cleavages. Carbamidomethyl [C] was set as fixed modification, while oxidation [M] was set as variable modifications. The target-decoy approach was used to filter the search results 39 , in which the false discovery rate was less than 1% at the peptide and protein level. LFQ (label-free quantification) and intensity-based absolute-proteinquantification were enabled.
For details on statistical analysis of proteomic data please see "Statistics and reproducibility. " . Viable myocytes were concentrated and the proper amount of medium was added in culture so that neighboring cells were not in direct contact. Viral constructs were permitted to express for 48 h with multiplicity of infection = 100-200. Adenoviral TTL-IRESdsRed and EMTB-3XGFP 7 were transduced in human myocytes as previously performed in rat myocytes 7 . To recover the maximal contractile function in cultured human myocytes, we found it important to replenish myocytes with fresh warm medium without cytochalasin D prior to calcium and contractility measurements.
Cell contractility. Experiments were performed as previously described 7 with some modification. Contractility was measured in custom-fabricated cell chambers (Ionoptix) mounted on an LSM Zeiss 880 inverted confocal microscope using a 40 × oil 1.4 numerical aperture objective and transmitted light camera (IonOptix MyoCam-S). Myocytes were maintained in normal Tyrode's solution (for freshly isolated myocytes) or culture medium (without cytochalasin D, for cultured myocytes) at room temperature and electrical field stimulation was provided at 0.5 Hz with a myopacer (IonOptix MYP100) through platinum electrodes lowered into the bath. Sarcomere length was measured optically by Fourier transform analysis (IonWizard, IonOptix). After 10-30 s of 0.5 Hz pacing to achieve steady state, five traces were recorded and analyzed. If not specified, contractility data was obtained at room temperature. The number of myocytes and hearts used in each experiment and further details are listed in Supplementary Table 6 .
To test whether the contractile improvement with microtubule destabilization remains under more physiological conditions, both 0.5 Hz and 1 Hz contractions at 37 °C were recorded and analyzed in a small subset of isolated human myocytes (one non-failing and one failing heart, Supplementary Fig. 5c ).
Imaging equipment and analysis. Confocal imaging was carried out on a Zeiss 880 laser scanning confocal microscope operating on an Axiovert Z1 inverted microscope equipped with a 40 × oil 1.4 numerical aperture objective. High-speed super-resolution imaging was carried out on a Zeiss 880 Airyscan confocal with a 40 × 1.4 oil numerical aperture objective. Image analysis was performed using ZEN Black software for Airyscan processing, which involves signal integration from the 32 separate subresolution detectors in the Airyscan detector and subsequent deconvolution of this integrated signal. Additional signal processing was performed in Image J (National Institutes of Health). For calculating the microtubule fraction of cell area (Fig. 2d) , image analysis was performed blinded to the experimental groups. A 2-μ m max intensity projection was produced from four 0.5-μ m confocal z-sections. The threshold to determine microtubule positive pixels was determined from the average fluorescence of three background regions that clearly demonstrated no microtubule staining within the cell. From the resulting binary images (Fig. 2d top) , the microtubule positive fraction of the total cell area was calculated for the dTyr-microtubule and Tyr-microtubule network (Fig. 2d bottom) . Then binary images of both dTyr-and Tyr-microtubule channels were overlaid to generate a binary image of the total microtubule network of the cell, which enables the quantification of total-microtubule area and ratio of dTyr-microtubule per total microtubule (Fig. 2d bottom) .
SIM was performed on a Deltavison OMX microscope, equipped with a Front Illuminated scientific complementary metal-oxide semiconductor camera (2,560 × 2,160 pixels), 6 color solid state illuminator, and 100 × 1.4 numerical aperture oil immersion lens powered by an OMX Master Workstation. . The tip was held in this indentation depth for 1 s, and retracted over 2 s. The Young's moduli were calculated automatically by the software, by fitting the force versus indentation curve to the Hertz equation. The Young's modulus (E) is derived from the fit of the initial 60% of the loading force-displacement curve (F(h)), the indenter tip radius (R), and indentation depth (h), according to the following formula, for which a Poisson's ratio (ν ) of 0.5 was assumed.
Number of myocytes and hearts used in this experiment and further details are listed in Supplementary Table 5 .
Statistics and reproducibility. Proteomic analysis and statistics.
Mass spectrometry was performed in multiple hearts (biologically independent samples) for each group ( Fig. 1 and Supplementary Fig. 1a-e) . Number of human hearts used (normal N = 7, cHyp N = 6, ICM N = 6, HCMpEF N = 4, HCMrEF N = 5, DCM N= 6) is stated in figure legends.
LFQ values measured by mass spectrometry were used to represent the expression levels of proteins. Box plots of sample variance indicate normal distributions in each sample ( Supplementary Fig. 1a , box represents upper and lower quantiles, line median, and whiskers 1.5 interquartile range). Duplicated protein entries with lower LFQ values were removed. Also, protein entries with a median LFQ value of 0 were removed to exclude proteins expressed at very low levels or undetected by mass spectrometry. This resulted in a trimmed list of 2,676 proteins, and LFQ values from this list were used to perform PCA. To obtain a general view of sample distribution among disease conditions and evaluate whether there is biased distribution toward certain gender or age groups, the 500 genes with the highest variance among all samples were input in PCA performed using the FactoMineR R software package. Samples in the PCA plots are color coded by disease groups, age, or gender to illustrate any distribution pattern/cluster based on these factors (Fig. 1a, Supplementary Fig. 1b-e and Supplementary Data). To concentrate on difference from the most variable proteins and discover the genes contributing to the difference, a two-dimensional PCA biplot was generated Articles NATure MeDiciNe (Supplementary Fig. 1b) . Mass spectrometry raw data were deposited in PRIDE with dataset identifier PXD008934.
Differential gene expression analysis was used to assess prominent changes in disease groups, resulting in a protein list ranked by statistical significance obtained from LIMMA, an R package with a linear model adjusting for age and sex. P values were adjusted for multiple testing using the Benjamini-Hochberg procedure. Figure 1d at the top left shows the top ten upregulated genes in HCMrEF and DCM groups, ranked by the adjusted P values from LIMMA analysis. Supplementary Table 2 is a summary of the top 25 up-and downregulated proteins from differential gene expression analysis. The ranked lists of top 500 upregulated genes in each group (compared to normal) were used for gene list functional enrichment analysis (ToppFun), performed on the ToppGene website 11 . The top 20 upregulated molecular function gene ontology groups in each comparison (see Supplementary  Table 3) were summarized and then compiled into a list of functionally nonredundant gene ontology groups (with more than 10% hit counts per input list in at least one of the comparisons). This list of gene ontology groups was expressed in a heat map (Fig. 1b) color coded by − log10 q-value B + H (statistical significance obtained from ToppFun analysis). Color coded heat maps based on log2 fold change (Fig. 1c) and dot plots of LFQ values (Fig. 1d) were also made to visualize protein expression shifts in specific cytoskeletal groups/genes of interest among disease groups. Morpheus (https://software.broadinstitute.org/morpheus/) was used to generate heat maps. Results of the domain enrichment analysis are available in Supplementary Table 4 .
Other data analysis and statistics. Statistical analysis and graphing were performed using Origin software (OriginLab, Northampton, MA Supplementary Figs. 1f, 2-6, all experiments were replicated in multiple hearts (biologically independent samples/independent experiments) for each condition, indicated by the N number in each figure and figure legend. The exact n values used to calculate statistics and the statistical tests for significance are stated in individual figure legends. In summary, where comparisons between sets were both repetitive and restricted, the Bonferroni multiple comparisons correction was used to adjust the significance threshold of two-sided t-tests accordingly (Figs. 2d,f, 4f ,g, 5a,d,f; Supplementary Fig. 5c ). Multiple comparisons analysis of variance (ANOVA) with post hoc Tukey test was used when multiple data sets shared a single control condition ( Fig. 3b; Supplementary Fig. 1f, 2c,d , 4e-g). Outlier exclusion was applied to immunofluorescence quantification data (Fig. 2d) exceeding 2 s.d . from the mean. Degrees of freedom for all ANOVA are equal to number of groups minus one (Fig. 3b, Supplementary Fig. 1f, 2c,d, 4e-g ). Degrees of freedom for all two-sample, two-sided t-tests are equal to the combined number of data points (n) minus two (Fig. 2d,f, Fig. 5a,d,f) , while degrees of freedom for all one-sample, two-sided t-tests are equal to n minus one (Fig. 4f,g,  Supplementary Fig. 5c ).
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. The datasets generated or analyzed for the current study are available from the corresponding author upon reasonable request. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 40 partner repository with the dataset identifier PXD008934. Figure 1, Supplementary Fig. 1 , and Supplementary Tables 2-4 were generated from this associated source data.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Image analysis was performed using ZEN Black software for Airyscan processing. Additional signal processing was performed in Image J (NIH). Image studio lite was used for western blot quantification. OriginPro was used for graphing and statistical analysis. R software packages FactoMineR and Limma, and Toppgene (https://toppgene.cchmc.org) were used for proteomic analysis. Morpheus (https://software.broadinstitute.org/morpheus/) was used to generate heatmaps.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials used are readily available from the authors or from standard commercial sources.
